ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.77
-0.15%
US Tech 100
21,094.80
0.10%
S&P 500
6,075.32
0.23%
US Dollar vs CAD
1.43095
-0.05%
Bitcoin
96,623.86
0.00%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. AstraZeneca PLC (AZN)

  7. AstraZeneca PLC (AZN) News

AZN

AstraZeneca (AZN)

AstraZeneca PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AZN
DateTimeSourceHeadlineSymbolCompany
02/06/20258:53AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
02/06/20256:00AMBusiness WireAstraZeneca’s Full Year and Q4 2024 resultsNASDAQ:AZNAstraZeneca PLC
02/06/20254:45AMPR Newswire (US)The Gross Law Firm Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming Deadline - AZNNASDAQ:AZNAstraZeneca PLC
02/05/202511:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:AZNAstraZeneca PLC
02/03/202512:05PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
02/03/20255:23AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
02/03/20254:45AMPR Newswire (US)Shareholders that lost money on AstraZeneca PLC(AZN) Urged to Join Class Action - Contact The Gross Law Firm to Learn MoreNASDAQ:AZNAstraZeneca PLC
01/30/20254:45AMPR Newswire (US)AZN LAWSUIT ALERT: The Gross Law Firm Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming DeadlineNASDAQ:AZNAstraZeneca PLC
01/27/20255:00PMBusiness WireENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapiesNASDAQ:AZNAstraZeneca PLC
01/27/20254:45AMPR Newswire (US)Shareholders of AstraZeneca PLC Should Contact The Gross Law Firm Before February 21, 2025 to Discuss Your Rights - AZNNASDAQ:AZNAstraZeneca PLC
01/23/20251:33PMPR Newswire (Canada)AstraZeneca prévoit un investissement de 820 M$ CA (570 M$ US) au Canada pour consolider son statut grandissant de plaque tournante mondiale et faire progresser la réalisation d'essais cliniquesNASDAQ:AZNAstraZeneca PLC
01/23/20251:32PMPR Newswire (Canada)AstraZeneca plans C$820 million (US$570m) investment in Canada to advance growing global hub and clinical deliveryNASDAQ:AZNAstraZeneca PLC
01/23/20254:45AMPR Newswire (US)AstraZeneca PLC Sued for Securities Law Violations - Contact The Gross Law Firm Before February 21, 2025 to Discuss Your Rights - AZNNASDAQ:AZNAstraZeneca PLC
01/23/20254:00AMPR Newswire (US)AstraZeneca PLC Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AZNNASDAQ:AZNAstraZeneca PLC
01/20/20254:45AMPR Newswire (US)The Gross Law Firm Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming Deadline - AZNNASDAQ:AZNAstraZeneca PLC
01/17/20254:35PMBusiness WireDATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancerNASDAQ:AZNAstraZeneca PLC
01/17/20256:00AMBusiness WireCALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphomaNASDAQ:AZNAstraZeneca PLC
01/16/20254:45AMPR Newswire (US)Shareholders that lost money on AstraZeneca PLC(AZN) should contact The Gross Law Firm about pending Class Action - AZNNASDAQ:AZNAstraZeneca PLC
01/13/20256:00AMBusiness WireDatopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancerNASDAQ:AZNAstraZeneca PLC
01/13/20254:45AMPR Newswire (US)Shareholders that lost money on AstraZeneca PLC(AZN) should contact The Gross Law Firm about pending Class Action - AZNNASDAQ:AZNAstraZeneca PLC
01/09/20254:45AMPR Newswire (US)Shareholders that lost money on AstraZeneca PLC(AZN) Urged to Join Class Action - Contact The Gross Law Firm to Learn MoreNASDAQ:AZNAstraZeneca PLC
01/02/202512:50PMPR Newswire (US)AstraZeneca PLC Class Action: The Gross Law Firm Reminds AstraZeneca Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025 - AZNNASDAQ:AZNAstraZeneca PLC
01/02/20259:42AMPR Newswire (US)AstraZeneca PLC Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AZNNASDAQ:AZNAstraZeneca PLC
12/30/20244:45AMPR Newswire (US)Class Action Filed Against AstraZeneca PLC (AZN) - February 21, 2025 Deadline to Join - Contact The Gross Law FirmNASDAQ:AZNAstraZeneca PLC
12/18/20248:05AMPR Newswire (Canada)Alexion, la division des maladies rares d'AstraZeneca, et l'Alliance pharmaceutique pancanadienne (APP) parviennent à un accord au sujet de Koselugo (sélumétinib) pour le traitement des enfants atteints de neurofibromatose de type 1 (NF1) présentant deNASDAQ:AZNAstraZeneca PLC
12/18/20248:05AMPR Newswire (Canada)Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Koselugo (selumetinib) for the treatment of paediatric patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform nNASDAQ:AZNAstraZeneca PLC
12/11/20249:15AMBusiness WireLYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trialNASDAQ:AZNAstraZeneca PLC
12/09/20246:00AMBusiness WireDatopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancerNASDAQ:AZNAstraZeneca PLC
12/08/202410:00AMBusiness WireFixed-duration CALQUENCE plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in AMPLIFY Phase III trialNASDAQ:AZNAstraZeneca PLC
12/06/20246:00AMBusiness WireIMFINZI® (durvalumab) granted Priority Review in the US ​for patients with muscle-invasive bladder cancerNASDAQ:AZNAstraZeneca PLC
 Showing the most relevant articles for your search:NASDAQ:AZN

Your Recent History

TG
A3KLCB
Tyco Elec
USOTC
CAGR
California Grapes (CE)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads